COMPASS Pathways (CMPS) Scheduled to Post Quarterly Earnings on Wednesday

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

COMPASS Pathways Trading Up 0.9 %

NASDAQ:CMPS traded up $0.08 on Monday, reaching $8.61. The company's stock had a trading volume of 189,012 shares, compared to its average volume of 662,041. The firm has a market cap of $533.30 million, a PE ratio of -3.60 and a beta of 2.39. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The business's 50-day moving average price is $9.51 and its two-hundred day moving average price is $8.51. COMPASS Pathways has a 1-year low of $5.01 and a 1-year high of $12.75.

Insider Buying and Selling at COMPASS Pathways

In other news, Director Ekaterina Malievskaia sold 11,862 shares of the firm's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $10.06, for a total value of $119,331.72. Following the completion of the transaction, the director now owns 4,110,338 shares in the company, valued at approximately $41,350,000.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other COMPASS Pathways news, Director Ekaterina Malievskaia sold 11,862 shares of the company's stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $10.06, for a total value of $119,331.72. Following the sale, the director now owns 4,110,338 shares in the company, valued at $41,350,000.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director George Jay Goldsmith sold 15,740 shares of the firm's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total transaction of $166,529.20. Following the sale, the director now owns 4,079,107 shares of the company's stock, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 150,222 shares of company stock worth $1,418,669. Insiders own 4.25% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CMPS. Morgan Stanley assumed coverage on COMPASS Pathways in a research note on Monday, April 1st. They set an "overweight" rating and a $30.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $120.00 target price on shares of COMPASS Pathways in a research note on Friday, March 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a research note on Tuesday, April 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.